Tags

Type your tag names separated by a space and hit enter

[Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Clin Calcium. 2007 Jan; 17(1):88-92.CC

Abstract

Calcimimetics drug such as cinacalcet suppress the secretion of parathyroid hormone by sensitizing parathyroid calcium receptors to extracellular ionized calcium. Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce elevation of serum calcium. And some studies were reported the use of cinacalcet not only to manage primary hyperparathyroidism, but also secondary hyperparathyroidism in nondialyzed stage, renal transplant patients and parathyroid carcinoma.

Authors+Show Affiliations

Toranomon Hospital, Nephrology Center.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

jpn

PubMed ID

17211098

Citation

Nakanishi, Shohei, and Masafumi Fukagawa. "[Therapeutic Agents for Disorders of Bone and Calcium Metabolism. the Calcimimetic Cinacalcet HCl]." Clinical Calcium, vol. 17, no. 1, 2007, pp. 88-92.
Nakanishi S, Fukagawa M. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl]. Clin Calcium. 2007;17(1):88-92.
Nakanishi, S., & Fukagawa, M. (2007). [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl]. Clinical Calcium, 17(1), 88-92.
Nakanishi S, Fukagawa M. [Therapeutic Agents for Disorders of Bone and Calcium Metabolism. the Calcimimetic Cinacalcet HCl]. Clin Calcium. 2007;17(1):88-92. PubMed PMID: 17211098.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl]. AU - Nakanishi,Shohei, AU - Fukagawa,Masafumi, PY - 2007/1/11/pubmed PY - 2007/3/24/medline PY - 2007/1/11/entrez SP - 88 EP - 92 JF - Clinical calcium JO - Clin Calcium VL - 17 IS - 1 N2 - Calcimimetics drug such as cinacalcet suppress the secretion of parathyroid hormone by sensitizing parathyroid calcium receptors to extracellular ionized calcium. Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce elevation of serum calcium. And some studies were reported the use of cinacalcet not only to manage primary hyperparathyroidism, but also secondary hyperparathyroidism in nondialyzed stage, renal transplant patients and parathyroid carcinoma. SN - 0917-5857 UR - https://wwww.unboundmedicine.com/medline/citation/17211098/[Therapeutic_agents_for_disorders_of_bone_and_calcium_metabolism__The_calcimimetic_cinacalcet_HCl]_ DB - PRIME DP - Unbound Medicine ER -